AMS Newsletter April 2025

In this edition

• Menopause Essentials Update
• Menopausal Hormone Therapy (MHT) discontinuation and shortages March 2025
• AMS Webinar: After the IMS World Congress 2024 - Your queries, dilemmas and tricky questions answered archive
• AMS Congress 2025 - Fremantle WA
• Health Services Research Grants 2025

Health Professionals - join AMS for Members-only content 

• The Menopause Society’s 2025 Annual Meeting
• European Menopause and Andropause Society (EMAS) Newsletter

In this edition

AMS News

This Menopause Essentials Update is designed as a wrap up of evidence-based management options for menopause and midlife health. Starting with structuring the initial consultation in the most effective way and finishing with a discussion of complex cases, the Menopause Essentials Update includes the latest on hormonal and non-hormonal options and up to date best-practice risk management recommendations across the full spectrum of menopause medicine.

Book here

Speakers include: Dr Amie Hanlon, Dr Christina Jang, Dr Samantha Kerr, and Dr Hannah Farquhar. 

9.00 am	The menopause consultation: Dr Samantha Kerr
9.40 am	Prescribing menopausal hormone therapy: Dr Hannah Farquhar
10.20 am	Morning Tea
10.50 am	Non-hormonal therapies: Dr Christina Jang
11.30 am	Management of bleeding on and off MHT: Dr Amie Hanlon
12.10 am	Panel discussion (all speakers): Cases | Q+A

CPD Points available:

The Menopause Essentials Update in Brisbane will run for 4 hours. It has been approved by ACRRM as 2.5hrs EA and 1hr RP (Activity number 36507)

CPD approval pending for RACGP and RANZCOG.

AMS Webinar: After the IMS World Congress 2024 - Your queries, dilemmas and tricky questions answered

The AMS Webinar is now available for review. 

If you did not have the opportunity to attend the webinar the archive version (also with CPD points) is now available on https://elearning.menopause.org.au/   

Menopausal Hormone Therapy (MHT) discontinuation and shortages April 2025

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia. Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

	Availability and expected supply due		Alternative supply under Section 19A
Dose	Estradot	Estraderm	Estramon	Estradiol Transdermal System
25 mcg	Unavailable - 31 Dec 2025	Limited - 30 June 2025	Available
37.5 mcg	Unavailable - 30 Jun 2025		Available	Available
50 mcg	Unavailable - 31 Dec 2025	Limited - 30 June 2025	Available	Unavailable
75 mcg	Unavailable - 31 Dec 2025	Limited - 30 June 2025	Available	Unavailable
100 mcg	Unavailable - 31 Dec 2025	Limited - 30 June 2025	Available	Available

Combined patches

Dose	Estalis Sequi	Estalis Conti
50/140	Unavailable – 30 June 2025	Unavailable – 30 June 2025
50/250	Unavailable – 30 June 2025	Limited – 30 June 2025

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

New Zealand

As at 14^th April 2025, patch availability is provided below.

Dose	Estradot	Viatris	Estraderm MX
25mcg	Limited	Available	Available
50mcg	Limited	Available
75mcg	Limited	Available
100mcg	Limited	Available

More information can be found here  

The AMS Guide to MHT Doses (New Zealand only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in New Zealand.

AMS Congress 2025 - Fremantle WA

Registration now open https://www.amscongress.com.au

Health Services Research Grants 2025

The HCF Research Foundation Health Services Research Grants 2025 program is now open for expressions of interest.

The 15th annual call for research projects will deliver funding to the research community from 1 January 2026.

This year's Grant Round will involve an Expression of Interest (EOI) stage prior to full Application.

The foundation invites an expression of interest if your health services research project addresses one of the following areas:

1. Structural and employment design approaches that improve the satisfaction and retention of the healthcare workforce leading to improved care continuity, patient safety and health outcomes and supporting the sustainability of the health care system.
2. Evaluation of acute hospital avoidance programs and approaches to address frequent and/or unnecessary emergency presentations.
3. Implementation strategies for pain management models of care that reduce the risk of pain chronicity and opioid overuse and addiction.

More information can be found here 

Expressions of interest close 5pm on Monday 19th May 2025 (AEST).

If you have any questions in relation to the application process, please read through the application guidelines. If you require further clarification, please contact the foundation by email: hcffoundation@hcf.com.au.

Health Professionals - join AMS for Members-only content 

The Menopause Society’s 2025 Annual Meeting

European Menopause and Andropause Society (EMAS) Newsletter AMS is an affiliate of EMAS. See latest copy.